中国药物警戒 ›› 2024, Vol. 21 ›› Issue (2): 208-210.
DOI: 10.19803/j.1672-8629.20230492

• 安全与合理用药 • 上一篇    下一篇

注射用奥沙利铂致全身肌肉疼痛1例分析

方美琳1,2, 郑慧敏1,2, 王存泽1,2, 王凌1,2#, 阮君山1,2,*   

  1. 1福建医科大学省立临床医学院,福建省立医院,福建 福州 350001;
    2福建医科大学药学院,福建 福州 350004
  • 收稿日期:2023-08-16 出版日期:2024-02-15 发布日期:2024-02-06
  • 通讯作者: *阮君山,男,博士,主任药师,临床药学。E-mail: ruanjunshan@163.com。#为共同通信作者。
  • 作者简介:方美琳,女,硕士,临床药学。
  • 基金资助:
    福建省卫生健康中青年骨干人才培养项目（2022GG- A001）

One case of generalized myalgia caused by oxaliplatin

FANG Meilin1,2, ZHENG Huimin1,2, WANG Cunze1,2, WANG Ling1,2#, RUAN Junshan1,2,*   

  1. 1Department of Pharmacy, Fujian Provincial Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou Fujian 350001, China;
    2School of Pharmacy, Fujian Medical University, Fuzhou Fujian 350004, China
  • Received:2023-08-16 Online:2024-02-15 Published:2024-02-06

PDF (PC)

136

摘要： 目的 研究注射用奥沙利铂在胃癌患者治疗中的安全性。方法 对1例51岁男性患者因恶性肿瘤术后化疗给予奥沙利铂治疗出现全身肌肉疼痛诊疗过程进行回顾性分析。结果 实验室检查：糖类抗原CA19-9 6.09 U·mL-1,CA72-4 2.61 U·mL-1,CA15-3 6.99 U·mL-1,癌胚抗原 2.45 ng·mL-1,甲胎蛋白1.76 ng·mL-1,肌酸激酶CK49 U·L-1,血清肌酐83 μmol·L-1,经实验室检查与辅助检查排除其他原因导致的全身肌肉疼痛,考虑为奥沙利铂引起的不良反应。停用奥沙利铂后,次日患者诉肌肉疼痛减轻,VAS评分7分。停药1周后患者肌肉疼痛消失,VAS评分0分。结论 注射用奥沙利铂可能会增加全身肌肉疼痛不良反应发生的风险,临床需警惕。

关键词: 奥沙利铂, 注射, 肌肉疼痛, 药品不良反应, 胃癌, 化疗, 肿瘤

Abstract: Objective To study the safety of oxaliplatin for injection in patients with gastric cancer. Methods The process of treating one 51-year-old male patient who developed generalised myalgia as a result of postoperative chemotherapy for a malignant tumor after being given oxaliplatin was analyzed. Results The laboratory test tests were as follows: the level of carbohydrate antigen was 19-9 (CA19-9) 6.09 U·mL-1, CA72-4 was 2.6 U·mL-1, CA15-3 was 6.99 U·mL-1, carcinoembryonic antigen was 2.45 ng·mL-1, alpha fetoprotein was 1.76 ng·mL-1, creatine kinase (CK) was 49 U·L-1, and serum creatinine (SCr) was 83 μmoL·L-1. After other causes of generalized myalgia were ruled out, the possibility of adverse reactions being caused by oxaliplatin was taken into account. Upon discontinuation of oxaliplatin, the patient reported reduced muscle soreness, with a VAS score of 7. One week later, the patient’s muscle soreness completely disappeared, resulting in a VAS score of 0. Conclusion Oxaliplatin for injection may increase the risk of generalised muscle pain, so clinical vigilance is required.

Key words: oxaliplatin, injection, myalgia, adverse drug reaction, gastric cancer, chemotherapy, tumor

中图分类号: